Research identifies CD8+ HD TEMRA as a biomarker predicting disease recurrence in head and neck cancer, suggesting effective flow cytometry gating strategies.
Key Points
The aim is to determine the minimal necessary flow cytometry markers for prognostic identification of TEMRA cells in HNSCC.
Investigated a surgically treated HNSCC cohort for prognostic T cell populations.
Identified high levels of CD8+ HD TEMRA cells using flow cytometry.
Developed gating strategies for clinical utility in predicting disease recurrence.
Identified CD8+ HD TEMRA as a prognostic biomarker associated with early disease recurrence.
Gating on live CD8+ CD57+ cells predicts recurrence with > 41.2% HD TEMRA in oral cancer patients.